Company: EDSA
Filing Date: 2025-12-12
Form Type: 10-K
Source: 0001171843-25-007914
Chunk: 374

Company: Edesa Biotech, Inc.
Filing Date: 2025-12-12
Form: 10-K
Item: Item 1A
Chunk 374
---

			$
			10,792,172

			$
			1,037,320

The accompanying notes are an integral part of these consolidated financial statements.

F-6

EDESA BIOTECH, INC.

Consolidated Statements of Changes in Shareholders’ Equity

			Shares #

			Common Shares

			Series A-1 Preferred Shares 

			Series B-1 Preferred Shares 

			Additional Paid-in Capital

			Accumulated Other Comprehensive Loss

			Accumulated Deficit

			Total Shareholders' Equity

			Balance - September 30, 2023

			3,075,473

			$
			46,643,151

			$
			-

			$
			-

			$
			13,039,265

			$
			(214,648
			)
			 
			$
			(52,418,968
			)
			 
			$
			7,048,800

			Issuance of common shares upon exercise of warrants

			171,916

			729,387

			-

			-

			-

			-

			-

			729,387

			Issuance costs

			-

			(136,514
			)

			-

			-

			-

			-

			-

			(136,514
			)

			Share-based compensation

			-

			-

			-

			-

			537,492

			-

			-

			537,492

			Net loss and comprehensive loss

			-

			-

			-

			-

			-

			(27,965
			)

			(6,170,045
			)

			(6,198,010
			)

			Balance - September 30, 2024

			3,247,389

			$
			47,236,024

			$
			-

			$
			-

			$
			13,576,757

			$
			(242,613
			)
			 
			$
			(58,589,013
			)
			 
			$
			1,981,155

			Issuance of common shares

			3,862,